Novel Coronavirus Pneumonia Clinical Trial
Official title:
Study for Clinical Epidemiology and Methods of Diagnosis and Treatment of Novel Coronavirus Pneumonia (NCP)
To develop practical and effective clinical diagnosis and treatment schemes for the control of novel coronavirus pneumonia.
By retrospectively analyzing the clinical epidemiological characteristics of the novel coronavirus pneumonia and the current diagnosis and treatment schemes, as well as in-depth analyzing the disease development process and outcome trends of NCP patients to develop practical and effective clinical diagnosis and treatment schemes and provide guarantee for the rapid control of the epidemic. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04798716 -
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05305456 -
Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19
|
Phase 3 | |
Recruiting |
NCT04314271 -
The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia
|
||
Recruiting |
NCT04282902 -
A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection
|
Phase 3 | |
Withdrawn |
NCT04285190 -
The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19
|
N/A | |
Active, not recruiting |
NCT04273763 -
Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)
|
N/A | |
Completed |
NCT04280224 -
NK Cells Treatment for COVID-19
|
Phase 1 | |
Completed |
NCT04273321 -
Efficacy and Safety of Corticosteroids in COVID-19
|
N/A | |
Enrolling by invitation |
NCT04365309 -
Protective Effect of Aspirin on COVID-19 Patients
|
Phase 2/Phase 3 | |
Completed |
NCT04645407 -
Effects of Fuzheng Huayu Tablets on COVID-19
|
Phase 4 |